**Abstract and Introduction**

Platinum-based chemotherapy is a vital component of treatment for non-small cell lung cancer (NSCLC), but long-term prognosis is poor. Additionally, drug resistance continues to be a challenge. 

**Background**

Cisplatin (cisplatin) is a functional alkylating agent with proven activity against a variety of tumors, including NSCLC. 

**Methods**

The authors demonstrated activity against a variety of tumors, including NSCLC. 

**Results**

Our results support VAL as a viable treatment option for NSCLC patients who fail to respond to current platinum-based therapy. 

**Conclusion**

These results support non-overlapping mechanism of action between the platinum drugs and VAL, and support the potential for synergistic benefit for a combination of VAL and platinum-based therapies in the treatment of lung cancer, such as the cisplatin-HCT-116 model.